Noah M. Leibowitz
Partner | New York
Noah M. Leibowitz

Noah M. Leibowitz is an experienced first-chair trial attorney, focusing on intellectual property and complex litigation involving scientific, technical and medical expertise in the pharmaceutical, biotechnology, healthcare and high-tech sectors.

Mr. Leibowitz has led trial teams in numerous patent cases, including acting as lead counsel in winning two back-to-back jury verdicts within a month. He regularly represents innovator pharmaceutical companies in Hatch-Waxman cases, as well as pay-for-delay antitrust litigation, and litigation and arbitration over licensing and drug development deals. Mr. Leibowitz represented Daiichi Sankyo in Hatch-Waxman litigation to enforce Daiichi's patent on its multibillion dollar-dollar-per-year anti-ineffective Levaquin®, and in challenges to its BENICAR® (olmesartan), BENICAR® HCT (olmesartan / hydrochlorothiazide) and AZOR® (amlodipine / olmesartan) products. He also obtained a complete dismissal of all allegations against Daiichi Sankyo and its U.S. subsidiary as lead counsel in the Lipitor® (atorvastatin) pay-for-delay litigation. Mr. Leibowitz has represented Eli Lilly, GlaxoSmithKline and Human Genome Sciences in cases over the Cabilly patents, related to antibody manufacturing of Erbitux® (cetuximab) and Benlysta® (belimumab). Recently, he represented Dana-Farber Cancer Institute in litigation over the Honjo-Freeman patents related to anti-PD-1/PD-L1 immunotherapies, and Genzyme in patent litigation against Novartis over ZOLGENSMA® (onasemnogene abeparvovec-xioi).

In addition, Mr. Leibowitz negotiates complex intellectual property license agreements and provides advice on intellectual property issues in M&A transactions and securities offerings. He has taken part in well over 100 consummated or contemplated transactions and offerings for clients ranging from leading technology companies, to pharmaceutical companies at the forefront of innovation. 

Mr. Leibowitz has been routinely recognized as a patent “IP STAR” by Managing Intellectual Property. He is also routinely recognized by IAM Patent 1000 as a leading patent litigator in New York. In 2025, IAM stated he is a “seasoned attorney with a knack for staying ahead in the life sciences arena.” In 2024, he was described by IAM as a “litigator with a prowess for the life sciences; his patrons value his commitment to protecting their patents both through litigation and through preventative measures, including assessing potential infringements and risks, nationally and internationally.” In previous additions IAM noted him as having "abundant experience leading trial teams in Hatch- Waxman cases," and hailed him for “the business sense he brings to litigation, cultivated through extensive involvement in transactional IP practice." He has been consistently recognized by Super Lawyers as a leading intellectual property litigation lawyer in New York and has authored numerous articles in legal publications. He co-authored the chapter on "Special Considerations in Hatch- Waxman Litigation" in the second and third editions of Anatomy of a Patent Case, prepared by the Complex Litigation Committee of the American College of Trial Lawyers, as well as the chapter on American law in Intellectual Property in the Life Sciences.

Prior to joining Dechert, Mr. Leibowitz was a partner at Simpson Thacher & Bartlett.

  • Genzyme in patent litigation against Sarepta Therapeutics over ELEVIDYS® (delandistrogene - moxeparvovec-rokl), a prescription gene therapy used to treat Duchenne muscular dystrophy.
  • Baxter Healthcare in patent litigation brought by Eagle Pharmaceuticals over liquid bendamustine formulations for treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
  • Genzyme in patent litigation against Novartis over ZOLGENSMA® (onasemnogene abeparvovec-xioi), a gene therapy a gene therapy used to treat spinal muscular atrophy (SMA).
  • Dana-Farber Cancer Institute in litigation against Bristol-Myers Squibb over damages following correction of inventorship of the Honjo-Freeman patents related to anti-PD-1/PD-L1 immunotherapies.
  • Obtained a complete dismissal with prejudice of all allegations against Daiichi Sankyo and its U.S. subsidiary as lead counsel in the Lipitor “pay for delay” litigation. The decision was affirmed by the Third Circuit Court of Appeals and the Supreme Court denied certiorari.
  • Lead trial counsel for IOENGINE in cases involving secure USB storage devices. Two juries found all asserted claims of IOENGINE's patent valid and infringed, and awarded over US$12 million in damages for past infringement.
  • Daiichi Sankyo in an ICC arbitration seated in Singapore, stemming from its acquisition of a majority interest in Ranbaxy. The arbitral tribunal found that the former owners of Ranbaxy fraudulently concealed and misrepresented the nature and severity of FDA and DOJ investigations of Ranbaxy and awarded Daiichi Sankyo the rupee-denominated equivalent of over US$525 million, including fees, interest and costs.
  • Daiichi Sankyo (formerly Daiichi Pharmaceutical) in litigation to enforce Daiichi's patent on its multibillion dollar-dollar-per-year anti-ineffective LEVAQUIN® (levofloxacin) against numerous generic filers. The case against the first generic filer was won after a two month trial in the Northern District of West Virginia and affirmed by the Federal Circuit Court of Appeals. Cases against additional generic filers were resolved by successful motions for summary judgment.
  • Daiichi Sankyo in Hatch-Waxman challenges to BENICAR® (olmesartan), BENICAR® HCT (olmesartan / hydrochlorothiazide) and AZOR® (amlodipine / olmesartan) products. The cases were consolidated and tried to successful outcome in the District of New Jersey. The Federal Circuit Court of Appeals affirmed.
  • Eli Lilly in a challenge to the Cabilly patents over Lilly's cancer treatment ERBITUX® (cetuximab).
  • Human Genome Sciences in a series of patent and antitrust cases over HGS's BENLYSTA® (belimumab), the first FDA approved treatment for systemic lupus in over 50 years.

Includes matters handled at Dechert or prior to joining the firm.

  • 14th Annual Paragraph IV Disputes Conference — Virtual (October 6-7, 2020)

    Speaker, "Devising Strategies for Proving Infringement and Defending Validity" panel.
  • 35th Annual Joint Patent Practice Seminar — New York, NY (May 2, 2019)

    Speaker, "Hot Topics re. §101 and §102" breakout session.
Services Industries
    • Columbia University, B.A., 1996, magna cum laude
    • Columbia Law School, J.D., 1999, James Kent Scholar, Harlan Fiske Stone Scholar
    • New York
    • New Jersey
    • Supreme Court of the United States
    • United States Court of Appeals for the Federal Circuit
    • United States Court of Appeals for the Second Circuit
    • United States Court of Appeals for the Third Circuit
    • United States District Court for the Eastern District of New York
    • United States District Court for the Southern District of New York
    • United States District Court for the District of New Jersey